Glenn Carlson

748 total citations · 1 hit paper
25 papers, 575 citations indexed

About

Glenn Carlson is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Glenn Carlson has authored 25 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 8 papers in Surgery and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Glenn Carlson's work include Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Lipoproteins and Cardiovascular Health (5 papers) and Diabetes Treatment and Management (4 papers). Glenn Carlson is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Lipoproteins and Cardiovascular Health (5 papers) and Diabetes Treatment and Management (4 papers). Glenn Carlson collaborates with scholars based in United States, Sweden and United Kingdom. Glenn Carlson's co-authors include Renli Teng, Daniel D. Gretler, Michael Murphy, Dominick J. Angiolillo, Ann Hsu, John M. Leonard, Danièle Ouellet, G. Richard Granneman, John H. Cavanaugh and Sven Nylander and has published in prestigious journals such as The Lancet, Journal of the American College of Cardiology and Diabetologia.

In The Last Decade

Glenn Carlson

25 papers receiving 562 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

2023 71 citations Hiddo J.L. Heerspink, Arihiro Kiyosue et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Glenn Carlson United States	15	289	140	95	88	65	25	575
Claire Gozalo France	12	89 0.3×	131 0.9×	72 0.8×	60 0.7×	65 1.0×	34	491
Bény Charbit France	14	363 1.3×	336 2.4×	73 0.8×	39 0.4×	171 2.6×	31	1.3k
Aileen B Luzier United States	11	239 0.8×	69 0.5×	60 0.6×	16 0.2×	45 0.7×	17	482
Apichard Sukonthasarn Thailand	11	288 1.0×	143 1.0×	86 0.9×	40 0.5×	68 1.0×	47	641
Bernard E. Ilson United States	17	360 1.2×	112 0.8×	204 2.1×	27 0.3×	96 1.5×	33	825
F. Lagrange France	10	88 0.3×	54 0.4×	7 0.1×	51 0.6×	41 0.6×	47	386
Thierry Basset France	19	225 0.8×	324 2.3×	22 0.2×	124 1.4×	81 1.2×	53	1.0k
Zhanna Kobalava Russia	14	464 1.6×	130 0.9×	77 0.8×	58 0.7×	65 1.0×	237	846
Gayathri Kamalakkannan United States	6	502 1.7×	202 1.4×	195 2.1×	56 0.6×	130 2.0×	12	1.0k
A. Ravani Italy	13	432 1.5×	104 0.7×	85 0.9×	66 0.8×	67 1.0×	31	808

Countries citing papers authored by Glenn Carlson

Since Specialization

Citations

This map shows the geographic impact of Glenn Carlson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenn Carlson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenn Carlson more than expected).

Fields of papers citing papers by Glenn Carlson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glenn Carlson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenn Carlson. The network helps show where Glenn Carlson may publish in the future.

Co-authorship network of co-authors of Glenn Carlson

This figure shows the co-authorship network connecting the top 25 collaborators of Glenn Carlson. A scholar is included among the top collaborators of Glenn Carlson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glenn Carlson. Glenn Carlson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heerspink, Hiddo J.L., Arihiro Kiyosue, David C. Wheeler, et al.. (2023). Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. The Lancet. 402(10416). 2004–2017. 71 indexed citations breakdown →

Jain, Meena, Glenn Carlson, W. James Cook, et al.. (2018). Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus. Diabetologia. 62(3). 373–386. 11 indexed citations

Teng, Renli, et al.. (2017). Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects. Clinical Drug Investigation. 37(11). 1035–1045. 8 indexed citations

Angiolillo, Dominick J., Francesco Franchi, Ron Waksman, et al.. (2016). Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Journal of the American College of Cardiology. 67(6). 603–613. 35 indexed citations

Teng, Rongyue, Glenn Carlson, Sven Nylander, & Tomas Andersson. (2016). Effects of autologous platelet transfusion on platelet inhibition in ticagrelor‐treated and clopidogrel‐treated subjects. Journal of Thrombosis and Haemostasis. 14(12). 2342–2352. 35 indexed citations

Clavijo, Leonardo, Juan Maya, Glenn Carlson, et al.. (2015). Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. Cardiovascular revascularization medicine. 16(8). 450–454. 13 indexed citations

Waksman, Ron, Juan Maya, Dominick J. Angiolillo, et al.. (2014). TICAGRELOR VERSUS CLOPIDOGREL IN AFRICAN AMERICAN PATIENTS WITH CORONARY ARTERY DISEASE AND DIABETES MELLITUS. Journal of the American College of Cardiology. 63(12). A211–A211. 2 indexed citations

Price, Matthew J., Leonardo Clavijo, Dominick J. Angiolillo, et al.. (2014). A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. Journal of Thrombosis and Thrombolysis. 39(1). 8–14. 12 indexed citations

Teng, Renli, Glenn Carlson, & Judith Hsia. (2014). An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 53(2). 182–189. 19 indexed citations

10.

Waksman, Ron, Juan Maya, Dominick J. Angiolillo, et al.. (2014). CRT-99 ∗ Ticagrelor Versus Clopidogrel in African American Patients with Stable Coronary Artery Disease: A Randomized, Open-label, Multiple-dose, Crossover Study. JACC: Cardiovascular Interventions. 7(2). S6–S6. 1 indexed citations

11.

Teng, Renli, Glenn Carlson, & Judith Hsia. (2014). CRUSHING TICAGRELOR TABLETS ACCELERATES EXPOSURE COMPARED WITH INTACT TABLETS. Journal of the American College of Cardiology. 63(12). A229–A229. 2 indexed citations

12.

Carlson, Glenn, et al.. (2013). Evaluation of the Effect of Naloxegol on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT/QTc Study in Healthy Volunteers. Clinical Therapeutics. 35(12). 1876–1883. 26 indexed citations

13.

Nada, Adel, Gary A. Gintant, Robert Kleiman, et al.. (2013). The evaluation and management of drug effects on cardiac conduction (PR and QRS Intervals) in clinical development. American Heart Journal. 165(4). 489–500. 43 indexed citations

14.

Carlson, Glenn, Conrad Tou, Shamik Parikh, Bruce K. Birmingham, & Kathleen Butler. (2011). Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Therapy. 2(3). 123–132. 32 indexed citations

15.

Teng, Renli, et al.. (2004). A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor. The Journal of Clinical Pharmacology. 44(9). 1063–1071. 17 indexed citations

16.

Carlson, Glenn. (2001). The Value of Point-of-Care Testing When Instituting an Insulin Drip Protocol. Critical Care Nursing Quarterly. 24(1). 49–53. 5 indexed citations

17.

Ouellet, Danièle, Ann Hsu, G. Richard Granneman, et al.. (1998). Pharmacokinetic interaction between ritonavir and clarithromycin*. Clinical Pharmacology & Therapeutics. 64(4). 355–362. 64 indexed citations

18.

Ferry, James J., et al.. (1998). Pharmacokinetic Drug-Drug Interaction Study of Delavirdine and Indinavir in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 18(3). 252–259. 34 indexed citations

19.

Qian, Jiang, et al.. (1996). Evaluation of the Pharmacokinetic Interaction Between Ritonavir and Didanosine. Clinical Pharmacology & Therapeutics. 59(2). 144–144. 5 indexed citations

20.

Gretler, Daniel D., et al.. (1993). Diurnal Blood Pressure Variability and Physical Activity Measured Electronically and by Diary. American Journal of Hypertension. 6(2). 127–133. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact